好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Longitudinal Study of Hypersomnolence in the US General Population and its Chronicity
Sleep
P3 - Poster Session 3 (5:30 PM-6:30 PM)
7-039
To examine the prevalence, incidence and chronicity of hypersomnolence in the US general population as described in the DSM5; i.e., a self-reported excessive sleepiness despite a main sleep period lasting at least 7 hours.
Hypersomnolence is poorly defined in epidemiological studies, although its adverse implications for safety, health and optimal social and vocational functioning have been extensively reported.
The initial study was carried with 15,929 individualsfrom 15 US States. The longitudinal study was carried on in eight of these states. A total of 12,218 subjects were interviewed by phone during the first wave (W1) and 10,930 at the second wave (W2) three years apart. The analyses were carried on the subjects who participated in both interviews (N=10,930).
A total of 15.6% (15.0%-16.2%) of the sample had at least one symptom of hypersomnolence occurring at least 3 days per week for at least 3 months despite a sleep duration of at least 7 hours (Ohayon et al., 2012). At follow-up, 22.1% (21.9%-23.4%) reported hypersomnolence. The incidence per year was 5.7%. Hypersomnolence was chronic in 36.7% of cases. Hypersomnolence accompanied with distress or impairment was less frequent with a prevalence to 2.6% (2.4%-2.8%) in the original sample and 2.1% (1.8%-2.4%) at follow-up. Chronicity was lower (14.5%) suggesting that while hypersomnolence may still be present, its consequences on daytime functioning decreased over time.
Hypersomnolence is an important problem in the U.S. population and often chronic. It has to be taken seriously and requires attention from public health authorities, scientists and clinicians.
Authors/Disclosures
Maurice M. Ohayon, MD, PhD, DSc (Stanford)
PRESENTER 		The institution of Dr. Ohayon has received research support from Jazz pharmaceuticals. The institution of Dr. Ohayon has received research support from Takeda Pharmaceuticals.